에이치엘비는 끊임없는 열정과 노력으로 다양한 사업분야에서
미래의 변화를 주도하고 있습니다.
Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triplenegative breast cancer as third-l
The treatment of advanced triple-negative breast cancer, which failed in first-line or second-line therapy, is a significant challenge. We
conducted this retrospective study to explore the efficacy and safety of apatinib and capecitabine as the third-line treatment for
advanced triple-negative breast cancer.
This retrospective study involved 44 advanced triple-negative breast cancer patients who failed in first-line or second-line therapy
in Tangshan People’s Hospital from January 2016 to February 2017. Twenty-two patients received apatinib and capecitabine, while
22 patients were treated with capecitabine monotherapy as third-line therapy. The progression-free survival (PFS), objective
response rate (ORR), disease control rate (DCR), and adverse events were compared between 2 groups.
The apatinib and capecitabine group exhibited a higher PFS than capecitabine group (P=.001). Meanwhile, ORR and DCR in
apatinib and capecitabine group were better than in capecitabine group (P=.042; .016). The 2 groups showed no significant
difference in adverse events except degree I-II bleeding (P=.021). Both the apatinib and capecitabine and the capecitabine regimens
revealed good tolerability.
The apatinib and capecitabine regimen can achieve a better efficacy and similar serious adverse events compared with
capecitabine regimen as the third-line treatment for advanced triple-negative breast cancer.